Sign in
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Quality of Life and Retinal Disease During the COVID-19 Pandemic
Peter Y Zhao, MD
2021
The Updated AREDS Simplified Severity Scale for Age-Related Macular Degeneration, Incorporating Reticular Pseudodrusen
Tiarnan D Keenan, BM BCh, PhD
Updates from the Field
2024
Category: AMD-Non-Neovascular